0.47Open0.47Pre Close0 Volume826 Open Interest15.00Strike Price0.00Turnover133.06%IV54.70%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.47Extrinsic Value100Contract SizeAmericanOptions Type0.1497Delta0.0697Gamma44.44Leverage Ratio-0.0170Theta0.0008Rho6.65Eff Leverage0.0058Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet